Search

8 páginas, 2 figuras, 1 tabla., Ribosome biogenesis is an emerging therapeutic target. It has been proposed that cancer cells are addicted to ribosome production which is therefore considered a druggable pathway in cancer therapy. Cancer cells have been shown to be more sensitive to inhibition of the ribosome production than healthy cells. Initial attempts of inhibiting ribosome biogenesis have been focused on the inhibition of transcription by targeting RNA Pol I. Despite being a promising field of research, several limitations have been identified during the development of RNA Pol I inhibitors, like the lack of specificity or acquired resistance. Ribosome biogenesis is a multistep process and additional points of intervention, downstream the very initial stage, could be investigated. Eukaryotic ribosome maturation involves the participation of more than 200 essential assembly factors that will not be part of the final mature ribosome and frequently require protein-protein interactions to exert their biological action. Using mutagenesis, we have previously shown that alteration of the complex interface between assembly factors impairs proper ribosome maturation in yeast. As a first step toward the developing of ribosome biogenesis inhibitory tools, we have used our previously solved crystal structure of the Chaetomium thermophilum complex between the assembly factors Erb1 and Ytm1 to perform a structure-guided selection of interference peptides. The peptides have been assayed in vitro for their ability to bind their cellular partner using biophysical techniques., Funding was obtained from the Spanish Ministry of Economy, Industry and Competitiveness SAF2017-89901-R and Generalitat Valenciana PROMETEO/2018/055. Open access publication fees have been partially funded by URICI from Consejo Superior de Investigaciones Científicas (CSIC). Molecular graphics and analyses were performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311

21 páginas, 11 figuras, 4 tablas. Material suplementario en http://dx.doi.org/10.1016/j.jmb.2018.05.035, The Escherichia coli homodimeric proteins MnmE and MnmG form a functional complex, MnmEG, that modifies tRNAs using GTP, methylene-tetrahydrofolate, FAD, and glycine or ammonium. MnmE is a tetrahydrofolate- and GTP-binding protein, whereas MnmG is a FAD-binding protein with each protomer composed of the FAD-binding domain, two insertion domains, and the helical C-terminal domain. The detailed mechanism of the MnmEG-mediated reaction remains unclear partially due to incomplete structural information on the free- and substrate-bound forms of the complex. In this study, we show that MnmG can adopt in solution a dimer arrangement (form I) different from that currently considered as the only biologically active (form II). Normal mode analysis indicates that form I can oscillate in a range of open and closed conformations. Using isothermal titration calorimetry and native red electrophoresis, we show that a form-I open conformation, which can be stabilized in vitro by the formation of an interprotomer disulfide bond between the catalytic C277 residues, appears to be involved in the assembly of the MnmEG catalytic center. We also show that residues R196, D253, R436, R554 and E585 are important for the stabilization of form I and the tRNA modification function. We propose that the form I dynamics regulates the alternative access of MnmE and tRNA to the MnmG FAD active site. Finally, we show that the C-terminal region of MnmG contains a sterile alpha motif domain responsible for tRNA-protein and protein-protein interactions., This work was supported by the Spanish Ministry of Economy and Competitiveness (BFU2010-19737 and BFU2014-58673-P to M.-E.A.; BFU2016-78232-P to A.V.-C.), and Generalitat Valenciana(ACOMP/2012/065 to M.-E.A; PROMETEO/2012/061to J.B.). Funding for open access charge: [BFU2014-58673-P to M.-E.A.]

11 páginas, 5 figuras, 1 tabla. Contiene 5 figuras en material suplementario, en este fichero., Human Drg1, a guanine nucleotide binding protein conserved in archaea and eukaryotes, is regulated by Lerepo4. Together they form a complex which interacts with translating ribosomes. Here we have purified and characterized the GTPase activity of Drg1 and three variants, a shortened mutant depleted of the TGS domain, a phosphomimicking mutant and a construct with the two combined mutations. Our data reveal that potassium strongly stimulates the GTPase activity, without changing the monomeric status of Drg1 and that this activity is notably reduced in the mutants. The nature of Lerepo4 association has also been investigated. Dissecting the role of the different domains revealed that Dfrp domain is the sole responsible for the Drg1 increase in thermal stability and the four fold stimulation over its catalytic activity. Lerepo4 action leaves Drg1 affinity for nucleotides unaffected, feasibly favoring a switch I reorientation, mainly via the TGS domain. Drg1 displayed a high temperature optimum of activity at 42°C, suggesting the ability of being active under possible heat stress conditions., This work was supported by Ministerio de Ciencia e Innovación (SAF2009-10667, SAF2012-31405) and Generalitat Valenciana (Prometeo/2012/061), Spain.

24 páginas, 3 figuras, 1 tabla., In the era of biomedicines and engineered carrier systems, cell penetrating peptides (CPPs) have been established as a promising tool for therapeutic application. Likewise, other therapeutic peptides, successful in vivo application of CPPs will strongly depend on peptide stability, the bottleneck for this type of biodegradable molecules. In this review, the authors describe the current knowledge of the in vivo degradation for known CPPs and the different strategies available to provide a higher resistance to metabolic degradation while preserving cell penetration efficiency. Peptide stability can be improved by different means, either modifying the structure to make it unrecognizable to proteases, or preventing access of proteolytic enzymes by applying conformation restriction or shielding strategies.

3 páginas, 2 figuras, 1 tabla., Breast cancer metastasis suppressor 1 (BRMS1) is an inhibitor of metastatic progression and plays a role in several steps of the metastatic cascade. Apart from the ability of BRMS1 to negatively regulate metastasis formation in breast, melanoma and ovarian tumours, very little is known about the molecular aspects of the antimetastatic properties of BRMS1. Here, the expression, purification and crystallization of a functional fragment of human BRMS1 that is predicted to be a coiled-coil region are reported. The purified fragment crystallized in space group C222(1) using the vapour-diffusion method. The unit-cell parameters were a = 42.6, b = 191.3, c = 71.9 A. The crystals diffracted to 2.0 A resolution and a complete data set was collected under cryoconditions. This is the first structural report of BRMS1., This work was supported by Grant SAF2006-10269 of the “Ministerio de Ciencia y Tecnología” and Fundación Mutua Madrileña, Spain.